Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of vorasidenib plus temozolomide in IDH1/IDH2-mutant glioma
CTR20251399Phase 2Active
- Sponsor
- Servier
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorasidenib, temozolomide in glioma, astrocytoma, Oligodendroglioma (OG), sponsored by Servier. Started Jun 2025; status: active.
02
Drugs
vorasidenibtemozolomide
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on CTR20251399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251399.